Trial Profile
Phase II Study of CD62L+-Derived T Lymphocytes Transduced With a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients With NY-ESO-1 Expressing Melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mipetresgene autoleucel (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
- Indications Malignant melanoma
- Focus Therapeutic Use
- 11 Apr 2016 Primary endpoint changed to objective response with time frame of 3 months.
- 11 Apr 2016 Status changed from completed to discontinued.
- 26 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.